Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MoonLake Immunotherapeutics MLTX

Healthcare Biotechnology
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target... see more

Recent & Breaking News (NDAQ:MLTX)

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

GlobeNewswire 5 days ago

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire 11 days ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

GlobeNewswire September 9, 2024

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

GlobeNewswire August 7, 2024

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

GlobeNewswire June 10, 2024

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GlobeNewswire May 16, 2024

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire May 7, 2024

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

GlobeNewswire April 10, 2024

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewswire March 10, 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewswire March 4, 2024

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

GlobeNewswire February 29, 2024

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewswire February 26, 2024

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire November 14, 2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

GlobeNewswire November 5, 2023

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

GlobeNewswire October 15, 2023

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

GlobeNewswire October 11, 2023

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

GlobeNewswire October 4, 2023

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

GlobeNewswire September 6, 2023

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire August 10, 2023

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts  

GlobeNewswire July 25, 2023